Jiří Horáček

Jiří Horáček

Auto-generated profile, based on publicly available information

Jiří Horáček

National Institute of Mental Health, Topolová 748, Klecany, 250 67, Czech Republic

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2006 in CNS Drugs
Verified
Journal Article
Closed access
PDF file
JHJiri Horacek
Jiri Horacek
VBVera Bubenikova-Valesova
Vera Bubenikova-Valesova
MKMilan Kopecek
Milan Kopecek
TPTomas Palenicek
Tomas Palenicek
CDColleen Dockery
Colleen Dockery
CHCyril Höschl
Cyril Höschl

1 July 2008 in Neuroscience & Biobehavioral Reviews
Verified
Journal Article
Closed access
VBVěra Bubeníková-Valešová
Věra Bubeníková-Valešová
JHJiří Horáček
Jiří Horáček
MVMonika Vrajová
Monika Vrajová
CHCyril Höschl
Cyril Höschl

1 March 2014 in European Neuropsychopharmacology
Verified
Journal Article
Closed access
FTFilip Tylš
Filip Tylš
TPTomáš Páleníček
Tomáš Páleníček
JHJiří Horáček
Jiří Horáček

30 May 2014 in Frontiers in Behavioral Neuroscience
Verified
Journal Article
Open access
PDF file
TNTereza Nekovarova
Tereza Nekovarova
IFIveta Fajnerová
Iveta Fajnerová
JHJiri Horacek
Jiri Horacek
FSFilip Spaniel
Filip Spaniel
Schizophrenia is a complex neuropsychiatric disorder with variable symptomatology, traditionally divided into positive and negative symptoms, and cognitive deficits. Yet, the etiology of this disorder has yet to be fully understood.Recent findings suggest that alteration of the basic sense of self-awareness may be an essential distortion of schizophrenia spectrum disorders. In addition, extensive research of social and mentalizing abilities has stressed the role of distortion of social skills in schizophrenia.This article aims to propose and support a concept of triple brain network model of the dysfunctional switching between default mode and central executive network related to the aberrant activity of salience network. This model could represent a unitary mechanism of a wide array of symptom domains present in schizophrenia including the deficit of SELF (self-awareness and self-representation) and theory of mind (ToM) dysfunctions along with the traditional positive, negative and cognitive domains. We review previous studies which document the dysfunctions of SELF and ToM in schizophrenia together with neuroimaging data elucidating the triple brain network model as a common neuronal substrate of this dysfunction.

19 July 2007 in Neuropsychobiology
Verified
Journal Article
Closed access
JHJiri Horacek
Jiri Horacek
MBMartin Brunovsky
Martin Brunovsky
TNTomas Novak
Tomas Novak
LSLucie Skrdlantova
Lucie Skrdlantova
MKMonika Klirova
Monika Klirova
CHCyril Höschl
Cyril Höschl
Background: Auditory hallucinations are characteristic symptoms of schizophrenia with high clinical importance. It was repeatedly reported that low frequency (≤1Hz) repetitive transcranial magnetic stimulation (rTMS) diminishes treatment-resistant auditory hallucinations. A neuroimaging study elucidating the effect of rTMS in auditory hallucinations has yet to be published. Objective: To evaluate the distribution of neuronal electrical activity and the brain metabolism changes after low-frequency rTMS in patients with auditory hallucinations. Methods: Low-frequency rTMS (0.9 Hz, 100% of motor threshold, 20 min) applied to the left temporoparietal cortex was used for 10 days in the treatment of medication-resistant auditory hallucinations in schizophrenia (n = 12). The effect of rTMS on the low-resolution brain electromagnetic tomography (LORETA) and brain metabolism (18FDG PET) was measured before and after 2 weeks of treatment. Results: We found a significant improvement in the total and positive symptoms (PANSS), and on the hallucination scales (HCS, AHRS). The rTMS decreased the brain metabolism in the left superior temporal gyrus and in interconnected regions, and effected increases in the contralateral cortex and in the frontal lobes. We detected a decrease in current densities (LORETA) for the beta-1 and beta-3 bands in the left temporal lobe whereas an increase was found for beta-2 band contralaterally. Conclusion: Our findings implicate that the effect is connected with decreased metabolism in the cortex underlying the rTMS site, while facilitation of metabolism is propagated by transcallosal and intrahemispheric connections. The LORETA indicates that the neuroplastic changes affect the functional laterality and provide the substrate for a metabolic effect.

1 June 2016 in Behavioural Pharmacology
Verified
Journal Article
Closed access
FTFilip Tylš
Filip Tylš
TPTomáš Páleníček
Tomáš Páleníček
LKLukáš Kadeřábek
Lukáš Kadeřábek
MLMichaela Lipski
Michaela Lipski
AKAnna Kubešová
Anna Kubešová
JHJiří Horáček
Jiří Horáček
Psilocybin has recently attracted a great deal of attention as a clinical research and therapeutic tool. The aim of this paper is to bridge two major knowledge gaps regarding its behavioural pharmacology – sex differences and the underlying receptor mechanisms. We used psilocin (0.25, 1 and 4 mg/kg), an active metabolite of psilocybin, in two behavioural paradigms – the open-field test and prepulse inhibition (PPI) of the acoustic startle reaction. Sex differences were evaluated with respect to the phase of the female cycle. The contribution of serotonin receptors in the behavioural action was tested in male rats with selective serotonin receptor antagonists: 5-HT1Areceptor antagonist (WAY100635 1 mg/kg), 5-HT2Areceptor antagonist (MDL100907 0.5 mg/kg), 5-HT2Breceptor antagonist (SB215505 1 mg/kg) and 5-HT2Creceptor antagonist (SB242084 1 mg/kg). Psilocin induced dose-dependent inhibition of locomotion and suppression of normal behaviour in rats (behavioural serotonin syndrome, impaired PPI). The effects were more pronounced in male rats than in females. The inhibition of locomotion was normalized by 5-HT1Aand 5-HT2B/Cantagonists; however, PPI was not affected significantly by these antagonists. Our findings highlight an important issue of sex-specific reactions to psilocin and that apart from 5-HT2A-mediated effects 5-HT1Aand 5-HT2C/Breceptors also play an important role. These findings have implications for recent clinical trials.